FALLOPIAN TUBE NEOPLASMS
Clinical trials for FALLOPIAN TUBE NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new FALLOPIAN TUBE NEOPLASMS trials appear
Sign up with your email to follow new studies for FALLOPIAN TUBE NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo could slow ovarian Cancer's return
Disease control OngoingThis study tests whether adding the immunotherapy drug oregovomab to standard chemotherapy can help people with advanced ovarian cancer live longer without their cancer growing. About 615 newly diagnosed patients who had surgery to remove most of their cancer will receive either …
Matched conditions: FALLOPIAN TUBE NEOPLASMS
Phase: PHASE3 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated May 17, 2026 01:59 UTC
-
New combo therapy shows promise in ovarian cancer battle
Disease control OngoingThis study tests whether adding the immunotherapy drug oregovomab to standard chemotherapy can help people with advanced ovarian, fallopian tube, or peritoneal cancer. About 88 newly diagnosed patients will receive either the drug combo or chemo alone before surgery. The main goa…
Matched conditions: FALLOPIAN TUBE NEOPLASMS
Phase: PHASE2 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Ovarian cancer trial tests immune booster against resistant tumors
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (with or without bevacizumab) can slow the growth of ovarian cancer that has stopped responding to platinum-based treatments. About 643 adults with recurrent ovarian, fallopian tube, or …
Matched conditions: FALLOPIAN TUBE NEOPLASMS
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 04, 2026 16:30 UTC